Steminent Biotherapeutics Overview
- Year Founded
-
2007
- Status
-
IPO Registration
- Employees
-
57
- Latest Deal Type
-
IPO
- (Announced)
- Investors
-
6
Steminent Biotherapeutics General Information
Description
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan.
Contact Information
Website
www.steminent.comCorporate Office
- 4F-1, No. 12, Wenhu Street
- Neihu District
- Taipei, 114
- Taiwan
Corporate Office
- 4F-1, No. 12, Wenhu Street
- Neihu District
- Taipei, 114
- Taiwan
Steminent Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. IPO | 02-Sep-2026 | Announced | Generating Revenue | |||
| 4. Later Stage VC | 31-Aug-2023 | Completed | Generating Revenue | |||
| 3. Corporate | Completed | Generating Revenue | ||||
| 2. Corporate | 12-Oct-2021 | $800K | $1.7M | Completed | Generating Revenue | |
| 1. Corporate | 01-Jul-2017 | $901K | $901K | Completed | Generating Revenue |
Steminent Biotherapeutics Patents
Steminent Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023902528-A0 | Modified mesenchymal stem cells and uses thereof | Pending | 10-Aug-2023 | ||
| AU-2024273709-A1 | Methods for treating polyq disease and novel adipose tissue derived mesenchymal stem cells | Pending | 15-May-2023 | ||
| EP-4712989-A1 | Methods for treating polyq disease and novel adipose tissue derived mesenchymal stem cells | Pending | 15-May-2023 | ||
| US-20260284117-A1 | Methods for treating polyq disease and novel adipose tissue derived mesenchymal stem cells | Pending | 15-May-2023 | ||
| WO-2024235265-A1 | Methods for treating polyq disease and novel adipose tissue derived mesenchymal stem cells | Inactive | 15-May-2023 | A61K35/28 |
Steminent Biotherapeutics Signals
Steminent Biotherapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Daiwa Corporate Investment | Venture Capital | Minority | ||
| First Financial Holding | Corporation | Minority | ||
| Top Taiwan Venture Capital Group | Venture Capital | Minority | ||
| ReproCELL | Corporation | Minority | ||
| Giddi Pharma Company | Corporation | Minority |
Steminent Biotherapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Steminent Biotherapeutics FAQs
-
When was Steminent Biotherapeutics founded?
Steminent Biotherapeutics was founded in 2007.
-
Where is Steminent Biotherapeutics headquartered?
Steminent Biotherapeutics is headquartered in Taipei, Taiwan.
-
What is the size of Steminent Biotherapeutics?
Steminent Biotherapeutics has 57 total employees.
-
What industry is Steminent Biotherapeutics in?
Steminent Biotherapeutics’s primary industry is Biotechnology.
-
Is Steminent Biotherapeutics a private or public company?
Steminent Biotherapeutics is a Private company.
-
What is Steminent Biotherapeutics’s current revenue?
The current revenue for Steminent Biotherapeutics is .
-
How much funding has Steminent Biotherapeutics raised over time?
Steminent Biotherapeutics has raised $15.8M.
-
Who are Steminent Biotherapeutics’s investors?
Daiwa Corporate Investment, First Financial Holding, Top Taiwan Venture Capital Group, ReproCELL, and Giddi Pharma Company are 5 of 6 investors who have invested in Steminent Biotherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process